tirzepatide shortage resolved FDA confirms is still over, gives compounders a grace period Is Compound Tirzepatide Ending? FDA

In many cases, patients were troubled by unwanted side effects, or felt they didnt actually need the drug theyd been prescribed

Our study identified three characteristics that were associated with changes in HbA1c over the 12-month treatment period (Table 3)

Mi et al., 2023

This fibrous patch platform transforms combination chemotherapy from repetitive intravenous infusions into a single surgical or percutaneous implantation procedure, offering a translatable localized delivery strategy that integrates spatial drug compartmentalization, environmental responsiveness, and synergistic pharmacodynamics for regional breast cancer management [102]. In a recent investigation Abasalta et al